EP0447430A1 - Nouveaux peptides derives du facteur de necrose de tumeurs (tnf) - Google Patents

Nouveaux peptides derives du facteur de necrose de tumeurs (tnf)

Info

Publication number
EP0447430A1
EP0447430A1 EP90900107A EP90900107A EP0447430A1 EP 0447430 A1 EP0447430 A1 EP 0447430A1 EP 90900107 A EP90900107 A EP 90900107A EP 90900107 A EP90900107 A EP 90900107A EP 0447430 A1 EP0447430 A1 EP 0447430A1
Authority
EP
European Patent Office
Prior art keywords
group
peptide
val
protecting group
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP90900107A
Other languages
German (de)
English (en)
Inventor
Hans-Joachim Boehm
Lothar Daum
Andreas Haupt
Bernhard Schmied
Nigel Walker
Johann-Christian Zechel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Publication of EP0447430A1 publication Critical patent/EP0447430A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the invention relates to new peptides derived from tumor necrosis factor (TNF), their production and their use as medicaments.
  • TNF tumor necrosis factor
  • TNF TNF-related protein kinase
  • mice In addition to its cytotoxic properties, TNF is one of the main participants in inflammatory reactions (Pharmac. Res. 5, 129, 1988). The involvement of TNF in septic shock (Science 229, 869, 1985) and graft versus host disease (J. Exp. Med. 166, 1280, 1987) was shown in the animal model.
  • the invention relates to peptides of the formula I
  • A is Ser, Ala or Thr
  • B means Glu, Asp or Ser, X for a group G-, G-NH-CHM-CO-, G-NH-CHM-CO-W-, GR-NH-CHM-CO- or GR-NH-CHM- CO-W and
  • Y stands for a group Z-, -NH-CHQ-CO-Z, -V-NH-CHQ-CO-Z, -NH-CHQ-CO-UZ or -V-NH-CHQ-CO-UZ, where in X and Y
  • G represents a hydrogen atom or an amino protecting group
  • Z represents an OH or NH 2 group or a carboxyl protecting group
  • M and Q are hydrogen atoms or one of the groups
  • M and Q together form a - (CH 2 ) c -SS- (CH 2 ) d -, - (CH 2 ) e -CO-NH- (CH 2 ) f - or - (CH 2 ) e -NH-CO- (CH 2 ) g -NH-CO- (CH 2 ) f bridge (with c and d meaning a number from 1 to 4, e and f a number from 1 to 6 and g a number from 1 to 12) mean, and their salts with physiologically acceptable acids.
  • the peptides of formula I are made up of L-amino acids, but they can contain 1 to 2 D-amino acids.
  • the side chains of the trifunctional amino acids can carry protective groups or be unprotected.
  • Methanesulfonic acid acetic acid, formic acid, maleic acid, fumaric acid, malic acid, succinic acid, malonic acid, sulfuric acid, L-glutamic acid, L-aspartic acid, pyruvic acid, mucic acid, benzoic acid,
  • Glucuronic acid oxalic acid, ascorbic acid, acetylglycine.
  • the new compounds can be prepared by methods known in peptide chemistry.
  • the fragments in turn being able to be obtained by sequential construction from amino acids or in turn by fragment coupling.
  • the cyclic peptides are obtained by a cyclization reaction carried out in high dilution. Both in the sequential structure and in the fragment coupling, the building blocks must be linked by forming an amide bond. Enzymatic and chemical methods are suitable for this.
  • the coupling reagents can be used alone or in combination with additives such as N, N'-dimethyl-4-aminopyridine (DMAP), N-hydroxybenzotriazole (HOBt), N-hydroxybenzotriazine (HOOBt), N-hydroxysuccinimide (HOSu) or 2-hydroxypyridine .
  • DMAP N, N'-dimethyl-4-aminopyridine
  • HOBt N-hydroxybenzotriazole
  • HOOBt N-hydroxybenzotriazine
  • HSu N-hydroxysuccinimide
  • 2-hydroxypyridine 2-hydroxypyridine
  • Protective groups can be dispensed with, reversible protection of the reactive functional groups of the two reactants which are not involved in the formation of the amide bond is required for chemical synthesis.
  • three protecting group techniques known from the literature are preferred: the benzyloxycarbonyl (Z), the t-butyloxycarbonyl (Boc) and the 9-fluorenylmethyloxycarbonyl (Fmoc) protective group technique.
  • the protective group of the ⁇ -amino function of the chain-extending building block is designated in each case.
  • the side chain protecting groups of the trifunctional amino acids are chosen so that they are not necessarily split off together with the ⁇ -amino protecting group.
  • the peptide is typically built up sequentially on the polymeric support using the Boc or Fmoc protective group technique, the growing peptide chain at the C-terminus being covalently linked to the insoluble resin particles (see Figs. 1 and 2). This procedure allows reagents and by-products to be removed by filtration, making recrystallization of intermediate products unnecessary.
  • the protected amino acids can be bound to any suitable polymers which are only insoluble in the solvents used and must have a stable physical form which enables easy filtration.
  • the polymer must contain a functional group to which the first protected amino acid can be bound by a covalent bond.
  • a wide variety of polymers are suitable for this purpose, e.g.
  • All solvents which prove inert under the reaction conditions are suitable for peptide synthesis in solution, in particular water, N, N'-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), acetonitrile, dichloromethane (DCM), 1,4-dioxane, Tetrahydrofuran (THF), N-methyl-2-pyrrolidone (NMP) and mixtures of the solvents mentioned.
  • the peptide synthesis on the polymeric support can be carried out in all inert organic solvents in which the amino acid derivatives used are soluble; however, solvents which additionally have resin-swelling properties, such as DMF, DCM, NMP, acetonitrile and DMSO, and mixtures of these solvents are preferred.
  • the new peptides show good cytotoxic properties. Another part of the peptides has a high affinity for the cellular TNF receptor without, however, having any cytotoxic activity. They therefore represent TNF antagonists. In competition with natural TNF, they bind to the cellular TNF receptor and thus suppress the TNF effect.
  • the new peptides prove to be valuable medicinal products that are used for
  • neoplastic diseases and autoimmune diseases Treatment of neoplastic diseases and autoimmune diseases as well as for the control and prophylaxis of infections, inflammation and
  • Rejection reactions can be used in transplants. Simple experiments can be used to determine the mode of action of the individual peptides.
  • Simple experiments can be used to determine the mode of action of the individual peptides.
  • Cytotoxicity of the peptide was determined by incubating the cell line in the presence of the peptide. In a second experiment, you incubate the
  • the agonistic evaluation of the new peptides is based on their cytotoxic effects on TNF-sensitive cells (e.g. L929, MCF-7,
  • the L929 and MCF-7 test was performed as follows: 1. 100 ⁇ l of culture medium with 3 to 5 ⁇ 10 3 freshly trypsinized, exponentially growing L929 cells (mouse) or MCF-7 cells (human) were placed in the wells of a
  • the L929 culture medium contained 500 ml MEM Earle 1 ⁇ (Boehringer, Mannheim), 50 ml heat-inactivated (30 min, 56 ° C.) fetal calf serum (FCS), 50 ml L-glutamine (200 mM), 5 ml 100 ⁇
  • non-essential amino acids 3 ml 1M Hepes buffer pH 7.2 and 50 ml gentamycin (50 mg / ml).
  • the MCF-7 culture medium contained 500 ml of MEM Dulbecco 1x
  • the percentage of surviving cells in the cultures treated with peptide dilution was determined by means of crystal violet staining.
  • the liquids were removed from the wells by knocking off the test plate. 50 ⁇ l of crystal violet solutions were pipetted into each well.
  • the crystal violet solution had the following composition:
  • the antagonistic evaluation of the peptides is based on their
  • TNF-sensitive cells e.g. L929, MCF-7, A204, U937.
  • the L929 culture medium contained 500 ml of MEM Earle lx (Boehringer, Mannheim), 50 ml of FCS heat-inactivated for 30 min at 56 ° C., 5 ml of L-glutamine (200 mM), 5 ml of 100 ⁇ nonessential amino acids, 3 ml of IM Hepes Buffer pH 7.2 and 500 ⁇ l gentamycin (50 mg / ml).
  • the MCF-7 culture medium contained 500 ml MEM Dulbecco 1 ⁇ (Boehringer, Mannheim), 100 ml heat-inactivated (30 min, 56 ° C) FCS, 5 ml L-glutamine (200 mM) and 5 ml 100x nonessential amino acids.
  • the culture plate was then incubated for 48 hours at 37 ° C. in an atmosphere of water vapor-saturated air with 5 vol.% CO 2 .
  • the percentage of surviving cells in the solution-treated cultures was determined by crystal violet staining.
  • the liquids were removed from the wells by knocking off the test plate. 50 ⁇ l of crystal violet solutions were pipetted into each well.
  • the crystal violet solution had the one given in II.3
  • the crystal violet solution remained in the wells for 20 min and was then also knocked off.
  • the plates were then washed 5 times each by immersion in water to remove the non-cell-bound dye.
  • cell-bound dye was added by adding 100 ul
  • Reagent solution (50% ethanol, 0.1% glacial acetic acid, 49.9% water) extracted from the cells into each well. 4. By shaking the plates for 5 min each was obtained
  • rhu-TNF control defined the 50% competition value and the sample concentration, which leads to 50% competition of the rhu-TNF cytotoxicity at the presented rhu-TNF concentration, was determined as the antagonistic activity of the examined sample.
  • Indicator cells (eg U937) compete.
  • the medium contained 500 ml PBS (Boehringer, Mannheim), 10 ml heat-inactivated (30 min, 56 ° C) FCS and 100 mg sodium azide.
  • rhu-TNF lactoperoxidase method according to Bolton
  • NBS nonspecific binding
  • the 125 iodine-labeled rhu-TNF (1 ng 125 J-rhu-TNF in 100 ⁇ l medium) with a 200-fold excess of non-radioactively labeled rhu-TNF (200 ng rhu-TNF mixed in 100 ul medium).
  • 100 ⁇ l of medium with 2 ⁇ 10 6 u937 cells (human) were pipetted into the reaction vessels and mixed.
  • the reaction vessels (test volume 300 ⁇ l) were incubated at 0 ° C. for 90 min. After 45 minutes, the reaction batches were mixed again.
  • proteogenic amino acids are abbreviated in the examples with the well-known three-letter code.
  • Aad ⁇ -aminoadipic acid
  • Ac acetic acid
  • Ade 10-aminodecanoic acid
  • Ahp 7-aminoheptanoic acid
  • Ahx 6-aminohexanoic acid
  • Ano 9-aminononanoic acid
  • Aoc 8-aminooctanoic acid
  • Ape 5-aminopentanoic acid
  • Bai ß-alanine
  • Hey homocysteine
  • peptide resin (Pam or Merrifield resin) was suspended in DMF (15 ml / g resin) and, after addition with hydrazine hydrate (20 equivalents), stirred for 2 days at room temperature. For working up, the resin was filtered off and the filtrate
  • the peptide resin obtained according to Ib was dried in vacuo and then, depending on the amino acid composition, subjected to one of the following cleavage procedures (Wade, Tregear, Howard Florey Fmoc-Workshop Manual, Melbourne 1985).
  • the purity of the end products obtained was determined using analytical HPLC (stationary phase: 100 ⁇ 2, 1 mm VYDAC C-18, 5 ⁇ , 300 ⁇ ; mobile phase CH 3 CN / H 2 O gradient, buffered with 0.1% TFA, 40 ° C). Amino acid analysis and fast atom bombardment mass spectroscopy were used for characterization.
  • step 1-6 and 14-16 were carried out according to Ala).
  • the peptide resin was dried in vacuo; the yield was 1.14 g.
  • Boc-Glu (0Chx) -OH Boc-Cys (pMB) -OH implemented.
  • the resin was subjected to an HF cleavage according to All and the lyophilized crude product was taken up in 2 l of 0.1% acetic acid and the pH was then adjusted to 8.4 with aqueous ammonia. 0.01 N K 3 [Fe (CN) 6 ] solution was slowly added dropwise under an argon atmosphere until the yellowish-green color persisted for more than 15 min. The mixture was stirred for a further 1 h, then acidified to pH 4.5 with glacial acetic acid and 15 ml of an aqueous suspension of an anion exchanger (BIORAD 3 ⁇ 4A, chloride form) were added. After 30 minutes, the ion exchange resin was filtered off, the filtrate was concentrated to 100 ml on a rotary evaporator and then lyophilized.
  • an anion exchanger BIORAD 3 ⁇ 4A, chloride form
  • Example 28 Analogously to Example 28 can be prepared (for the synthesis of
  • Fmoc-Glu (OBzl) -OH implemented. After the synthesis was complete, the N-terminus was deprotected and acetylated (steps 2-4 and 8-9 were carried out according to Alb). The peptide resin was dried in vacuo; Yield 1.38 g.
  • the crude product (288 mg) obtained after the TFA cleavage according to AIII was dissolved in 500 ml degassed DMF. After addition of 0.2 ml of NEt 3 , 0.2 ml of diphenylphosphoryl azide was added at -25 ° C. and the mixture was stirred at -25 ° C. for 2 hours. The mixture was then stored at -20 ° C, 2 days at 4 ° C and 2 days at room temperature.
  • Fig. 1 The Boc protection group technique on the polymeric carrier
  • Boc t-butyloxycarbonyl protecting group
  • Fig. 2 The Fmoc protection group technique on the polymeric carrier

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne de nouveaux peptides ayant la formule: X-Pro-A-B-Y, dans laquelle A, B, X et Y ont la signification donnée dans la description, et leur procédé de production. Ces nouveaux peptides sont utiles pour traiter des maladies.
EP90900107A 1988-12-12 1989-12-02 Nouveaux peptides derives du facteur de necrose de tumeurs (tnf) Withdrawn EP0447430A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3841763A DE3841763A1 (de) 1988-12-12 1988-12-12 Neue tnf-peptide
DE3841763 1988-12-12

Publications (1)

Publication Number Publication Date
EP0447430A1 true EP0447430A1 (fr) 1991-09-25

Family

ID=6368958

Family Applications (1)

Application Number Title Priority Date Filing Date
EP90900107A Withdrawn EP0447430A1 (fr) 1988-12-12 1989-12-02 Nouveaux peptides derives du facteur de necrose de tumeurs (tnf)

Country Status (5)

Country Link
EP (1) EP0447430A1 (fr)
JP (1) JPH04502309A (fr)
CA (1) CA2005050A1 (fr)
DE (1) DE3841763A1 (fr)
WO (1) WO1990006947A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827821A (en) * 1987-12-10 1998-10-27 The Burnham Institute Conformationally stabilized cell adhesion peptides
EP0394326B1 (fr) * 1987-12-10 1996-07-31 La Jolla Cancer Research Foundation Methodes pour la production des peptides d'adhesion cellulaire a stabilisation conformationnelle
US6521594B1 (en) 1990-04-06 2003-02-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5648330A (en) * 1990-04-06 1997-07-15 La Jolla Cancer Research Foundation Method and composition for treating vascular graft occlusion
DK0527798T3 (da) * 1990-04-06 1997-12-15 Jolla Cancer Res Found Fremgangsmåde og sammensætning til behandling af thrombose
US5612311A (en) 1990-04-06 1997-03-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5780303A (en) * 1990-04-06 1998-07-14 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
DE4340111A1 (de) * 1993-11-22 1995-05-24 Schering Ag Tumor-Nekrose-Faktor-alpha inaktivierende Peptide
RU2067000C1 (ru) * 1994-06-29 1996-09-27 Владислав Исакович Дейгин Пептид и способ его получения
US7173110B2 (en) * 2004-11-08 2007-02-06 New York University Peptide anti-tumor agent

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5245290A (en) * 1975-10-08 1977-04-09 Hitachi Ltd Integrated circuit of semiconductor and method for its fabrication
US4415491A (en) * 1980-01-14 1983-11-15 The Regents Of The University Of California Synthetic vaccine peptide epitomes of hepatitis B surface antigen
EP0110791B1 (fr) * 1982-11-30 1990-04-25 Institut Pasteur Peptides comportant un site immunogène du poliovirus et ADNs contenant des séquences nucléotidiques codant pour ces peptides
US4518527A (en) * 1983-08-16 1985-05-21 Mitsubishi Chemical Industries Limited Polypeptides related to the pre-acetylcholine receptor-α of the electric organ of Torpedo californica
JPS60160125A (ja) * 1984-01-30 1985-08-21 Mitsubishi Electric Corp 半導体装置の製造方法
US4847080A (en) * 1984-03-07 1989-07-11 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipide vesicle carriers
US4556585A (en) * 1985-01-28 1985-12-03 International Business Machines Corporation Vertically isolated complementary transistors
JPS6231153A (ja) * 1985-08-02 1987-02-10 Matsushita Electric Ind Co Ltd Ｍｉｓ型半導体集積回路の製造方法
JPS6296390A (ja) * 1985-10-21 1987-05-02 Nec Corp 気相エピタキシヤル成長法
EP0247906B1 (fr) * 1986-02-04 1994-12-28 Mizuno, Den'Ichi ADN codant pour des polypeptides antitumoraux, les polypeptides et les agents antitumoraux contenant ces polypeptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9006947A1 *

Also Published As

Publication number Publication date
JPH04502309A (ja) 1992-04-23
CA2005050A1 (fr) 1990-06-12
WO1990006947A1 (fr) 1990-06-28
DE3841763A1 (de) 1990-06-13

Similar Documents

Publication Publication Date Title
DE69329425T2 (de) Dolastatin analog
DE69320339T2 (de) Derivate des Dolastatin
WO1990006943A2 (fr) Nouveaux peptides tnf
EP0447476A1 (fr) Nouveaux peptides derives du facteur de necrose de tumeurs (tnf)
EP0447430A1 (fr) Nouveaux peptides derives du facteur de necrose de tumeurs (tnf)
EP0447474A1 (fr) Nouveaux peptides derives du facteur de necrose de tumeurs (tnf)
DE3939797A1 (de) Neue vom neuropeptid y abgeleitete peptide
EP0447465A1 (fr) Nouveaux peptides derives du facteur de necrose de tumeurs (tnf)
WO1990006940A1 (fr) Nouveaux peptides derives du facteur de necrose de tumeurs (tnf)
EP0447472A1 (fr) Nouveaux peptides derives du facteur de necrose de tumeurs (tnf)
WO1990006939A1 (fr) Peptides tnf
EP0447431A1 (fr) Nouveaux peptides derives du facteur de necrose tumeurs (tnf)
EP0447429A1 (fr) Nouveaux peptides derives du facteur de necrose de tumeurs (tnf)
WO1992011285A1 (fr) Nouveaux peptides constituant des facteurs de necrose tumorale
DE4041188A1 (de) Neue tnf-peptide
EP0570375A1 (fr) Nouveaux peptides a activite anticoagulante.
DE4041189A1 (de) Neue-tnf-peptide

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19910425

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE ES FR GB IT LI LU NL

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

17Q First examination report despatched

Effective date: 19920710

18W Application withdrawn

Withdrawal date: 19920627